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Thioamide drugs, ethionamide (ETH) and pro-
thionamide (PTH), have been widely used for 
many years in the treatment of mycobacterial 
infections caused by Mycobacterium tuberculosis, 
M. leprae, and M. avium complex infections (1, 2). 
ETH and PTH are both bacteriocidal and are 
essentially interchangeable in a chemotherapy 
regimen. They are the most frequently used 
drugs for the treatment of drug-resistant 
  tuberculosis and, therefore, are becoming in-
creasingly relevant as the number of multidrug-
resistant and extensively drug-resistant cases is 
increasing worldwide (3, 4). Moreover, ETH 
and PTH are also used in a combined chemo-
therapy regimen with either dapsone or rifampin 
to treat leprosy (5). Although we have previ-
ously speculated about the mechanism of action 
of ETH in M. tuberculosis based on an analogy 
to isoniazid’s (INH’s) mode of action (6–8), 
defi  nitive biochemical evidence that ETH targets 
InhA has not been forthcoming.
ETH and PTH are structurally similar to 
INH (Fig. 1), and it is clear that all of these 
drugs inhibit mycolic acid biosynthesis (9, 10). 
It was demonstrated that a single amino acid 
mutation of inhA, S94A, was suffi   cient  to 
confer resistance to both ETH and INH in 
M. smegmatis, M. bovis (6, 11), and M. tuberculosis 
(8). Moreover, overexpression of inhA con-
ferred resistance to both INH and ETH in 
M. tuberculosis, M. bovis, and M. smegmatis (12). 
Indeed, several M. tuberculosis clinical isolates 
resistant to INH contain mutations in the inhA 
gene, and all have been found to be cross-resistant 
to ETH (13). These observations genetically 
demonstrated that the primary target of both 
INH and ETH was InhA, the enoyl-acyl ACP 
reductase involved in mycolic acid biosynthesis. 
In addition, subsequent biochemical analysis has 
clearly shown that the primary molecular target 
of INH is InhA (7, 8, 14–16).
INH is a prodrug that requires activation 
by KatG, a catalase-peroxidase (17, 18), to form 
an adduct with nicotinamide adenine dinucle-
otide (NAD+). It is the isonicotinic-acyl-NAD 
adduct that inhibits InhA (7, 8, 16). Although 
ETH is also a prodrug that requires activation 
to exert antitubercular activity, KatG mutant 
strains resistant to INH are sensitive to ETH, 
indicating that ETH has a diff  erent activator 
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(13, 19). Mutations of a gene designated ethA were repeat-
edly found in the clinical isolates resistant to ETH (13, 20). 
Like KatG, the overexpression of ethA in M. smegmatis re-
sulted in substantially increased ETH sensitivity (21). This 
evidence suggested that ethA is critical for the activation 
of ETH.
ethA encodes a fl  avin monooxygenase found to catalyze 
the Baeyer-Villiger reaction to detoxify aromatic and long-
chain ketones (22). The enzyme is membrane associated and has 
a tendency to form large oligomers after purifi  cation (22, 23). 
The monooxygenase activity of the purifi  ed EthA is very 
low (kcat = 0.00045 s−1), suggesting that the enzyme may re-
quire other proteins or cellular components to be completely 
functional (22). The active form of ETH has never been de-
tected or isolated in vitro, although some inactive metabolites 
produced by the catalytic oxidation of ETH by EthA have 
been studied by TLC and HPLC (20).
RESULTS AND D  I  S  C  U  S  S  I  O  N 
To identify the active form of ETH, we and others have at-
tempted to use purifi  ed EthA to activate ETH and inhibit 
InhA in vitro but have never been able to observe any InhA 
inhibition (unpublished data). Because in vitro activation of 
the drugs ETH and PTH has not been possible by either 
chemical or enzymatic approaches, we developed a cell-based 
activation method. In this system, recombinant M. tuberculosis 
EthA and InhA were co-overexpressed in the same Escherichia 
coli cell, and ETH or PTH was added to the culture to test 
whether the drugs would inhibit InhA upon activation. 
Although ETH and PTH are both potent drugs against 
M. tuberculosis (MIC =  0.5 μg/ml) (24), they do not aff  ect 
E. coli growth, even at very high concentrations (100 μg/ml), 
which is primarily caused by the absence of an EthA homo-
logue in E. coli.
InhA and EthA from M. tuberculosis were coexpressed in 
E. coli BL21 (DE3) in the presence of 100 μg/ml ETH. InhA 
was rapidly purifi  ed, and an in vitro enzyme assay was per-
formed. InhA isolated from the experimental sample had <1% 
of the specifi  c activity of InhA purifi  ed without the addi-
tion of ETH under the same assay condition. Mass analysis of 
denatured InhA from the experimental sample indicated the 
presence of a small molecule with a molecular weight of 
798.2 (Fig. S1, A and B, available at http://www.jem.org/
cgi/content/full/jem.20062100/DC1). This corresponds to 
the exact molecular weight of an ethyl- isonicotinic-acyl-
NAD covalent adduct. Moreover, pure fractions of this small 
Figure 2.  Active sites of the M. tuberculosis enoyl-acyl ACP reduc-
tases bound to inhibitors and the bound inhibitor. (A) The crystal struc-
ture of PTH-NAD superimposed onto the simulated annealing omit electron 
density map contoured at 1 σ. Carbon atoms are gray, oxygen atoms are 
red, nitrogen atoms are blue, and phosphor atoms are orange. The 2-propyl-
isonicotinic acyl group is covalently attached to the 4 position of the nico-
tinamide ring of NADH in a 4S confi  guration. (B) Cross section through the 
surface of the InhA active site with bound INH-NAD. (C) Cross section 
through the surface of the InhA active site with bound ETH-NAD showing 
that the 2-ethyl-isonicotinic acyl moiety protrudes into a hydrophobic binding 
pocket created by the rearrangement of the side chain of Phe149 (shown 
behind the transparent surface), which is similar to INH-NAD. (D) Cross 
section through the surface of the InhA active site with bound PTH-NAD, 
which has a similar binding mode to INH-NAD and ETH-NAD. The carbon 
atoms of the adduct inhibitors and Phe149 are white and yellow, respectively.
Figure 1.  Chemical structure of ETH, PTH, and INH. Although 
these prodrugs have similar structures, INH is activated by a 
catalase-peroxidase, whereas ETH and PTH are activated by a fl  avin-
 dependent  monooxygenase.JEM VOL. 204, January 22, 2007  75
BRIEF DEFINITIVE REPORT
molecule showed strong inhibition to native InhA in vitro 
(Ki = 7 ± 5 nM), which is as potent as the INH-NAD ad-
duct, the active form of INH (Ki = 5 nM) (8). When PTH 
was used in the same coexpression experiment, a compound 
with a molecular weight of 812.2 was identifi  ed that corre-
sponds to the exact weight of a propyl-isonicotinic-acyl-
NAD adduct (Fig. S1 C). This compound is also extremely 
potent against InhA in vitro (Ki = 2 ± 0.8 nM).
M. tuberculosis InhA in complex with the adducts was 
crystallized. X-ray diff  raction data to 2.2 and 2.5 Å resolution 
were collected from single crystals of ETH and PTH com-
plexes, respectively (Table S1, available at http://www.jem
.org/cgi/content/full/jem.20062100/DC1). Unbiased elec-
tron density maps of each complex clearly indicated the pres-
ence of a modifi  ed NAD with an ethyl-isonicotinic-acyl or 
propyl-isonicotinic-acyl group covalently attached to the 
4 position of the nicotinamide ring in a 4S confi  guration (Fig. 
2 A). The chemical structures of both inhibitors are consis-
tent with the molecular weights obtained by the mass analysis. 
Similar to the structure of InhA bound with the adduct 
INH-NAD (7), the ethyl-isonicotinic-acyl, or the propyl-
isonicotinic-acyl, moiety is found in a hydrophobic pocket 
that was formed by the rearrangement of the side chain of 
Phe149 (Fig. 2, B–D). The ethyl-isonicotinic acyl or the propyl-
isonicotinic-acyl group also forces the side chain of Phe149 to 
rotate  90°, forming an aromatic ring-stacking interaction 
with the pyridine ring (Fig. 3 A). The pocket is predomi-
nantly lined by hydrophobic groups from the side chains of 
Tyr158, Phe149, Met199, Trp222, Leu218, Met155, Met161, and 
Pro193, and is adjacent and partly overlapped with the fatty 
acyl substrate-binding site. Indeed, the atoms common to 
ETH-NAD, PTH-NAD, and INH-NAD are in nearly iden-
tical positions. The only diff  erence is the extra ethyl or pro-
pyl group at the 2 position of the pyridine ring of ETH or 
PTH. The ethyl group contributes to the binding of ETH-
NAD adduct by forming π-stacking interactions with the ar-
omatic side chain of Tyr158 at a distance of  3.3 Å. It is also 
within van der Waal interaction distances with side chains of 
Leu218 (3.3 Å) and Met155 (3.2 Å). The hydrogen-bonding 
inter  actions between the phosphate group of the adduct and 
residues of the nucleotide-binding site are well conserved. 
Therefore, it is very likely that mutations, such as S94A, that 
decrease the binding of NAD(H) and the INH-NAD adduct 
would also weaken the binding of ETH-NAD and PTH-
NAD (Fig. 4). This explains why the S94A mutant strain of 
M. tuberculosis is coresistant to both INH and ETH.
Other than ETH and PTH, thioamide drugs such as thi-
acetazone and isoxl have been shown to be activated by EthA 
(20). The same cell-based method was applied to test thiacet-
azone. The isolated InhA was not inhibited under the same 
assay condition. As expected, mass analysis did not show the 
existence of any tightly bound inhibitor. These results indi-
cate that, unlike ETH or PTH, thiacetazone does not target 
InhA, even though all of these thioamides are activated by 
EthA in M. tuberculosis.
Unlike INH, which is not eff  ective  against  M. leprae, 
most likely because of the dysfunction of M. leprae katG, 
ETH and PTH are used in the treatment of leprosy. Genome 
Figure 3.  M. tuberculosis InhA with bound inhibitors. (A) Stereo 
view of the superposition of active sites of the M. tuberculosis InhA:
NADH structure and the InhA:ETH-NAD structure, showing the side 
chain of Phe149 rotated  90° once the ETH-NAD adduct binds to the 
enzyme. The carbon atoms of residues and NADH in the InhA:NADH 
structure are cyan. The carbon atoms of residues and ETH-NAD in 
the InhA:ETH-NAD structure are gold. (B) The stereo view of the 
active sites of the M. leprae InhA:PTH-NAD structure. The carbon 
atoms of residues and PTH-NAD adduct are gold and cyan, respectively. 
Other atoms are colored according to the atom type (red, oxygen 
  atoms; blue, nitrogen atoms; yellow, sulfur atoms; and orange, 
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analysis indicated that both M. leprae and M. avium have ethA 
and inhA homologues with high sequence similarities to their 
M. tuberculosis counterparts. Therefore, the M. leprae ethA and 
inhA were coexpressed, in the presence of PTH using a cell-
based activation method similar to M. tuberculosis, as described 
in the second paragraph in Results and discussion. A com-
pound with the same molecular weight as PTH-NAD adduct 
was identifi  ed, which also showed strong inhibition to M. leprae 
InhA (Ki = 11 ± 6 nM) in vitro.
The crystal structure of M. leprae InhA in complex with 
PTH-NAD was solved to 2.1 Å resolution to compare the 
binding mode of the inhibitor with the enzyme with 
M. tuberculosis InhA. The overall structure of M. leprae InhA is 
similar to M. tuberculosis InhA (RMSD = 1.3 Å for Cαs), and the 
active site residues are conserved. The propyl-isonicotinic-
acyl moiety of the adduct is observed inside a hydrophobic 
pocket. The pyridyl ring forms a π-stacking interaction with 
the aromatic side chain of Phe149, and the propyl group is π 
stacking with the aromatic side chain of Tyr158. Residues, in-
cluding Ser94 in the nucleotide-binding site, form hydrogen-
bonding interactions with the phosphate group of the adduct 
in a similar manner as M. tuberculosis InhA (Fig. 3 B). These 
results supported our hypothesis that the active form of PTH 
inhibits M. leprae InhA in a similar way to M. tuberculosis InhA. 
Although no clinical or experimental mutant of M. leprae 
InhA has been reported thus far, based on the binding mode 
of the PTH-NAD adduct, it is very likely that the mutations 
of InhA found in ETH-resistant M. tuberculosis mutant strains, 
such as S94A, would also confer resistance of M. leprae to 
ETH and PTH.
Although ETH and INH NAD adducts are similar, their 
activation mechanisms are very diff  erent. INH, a hydrazid, 
is activated by the heme-using catalase-peroxidase KatG 
(16, 18). We proposed that INH was oxidized to generate an 
isonicotinic-acyl free radical, which subsequently attacked the 
NAD+ to form INH-NAD (7). ETH, a thioamide, has been 
shown to be metabolized by EthA, a FAD enzyme found in 
M. tuberculosis. It has been proposed that a free radical metabolite 
intermediate could be generated through EthA oxidation 
of ETH, similar to the activation of INH. However, no 
  active species that inhibit InhA were isolated in vitro (20), 
which suggests that an unknown cell component, either a 
protein or cell membrane, is required for the formation of the 
adduct by the free radical intermediate. We believe that the 
inactive metabolites isolated in previous attempts could result 
from side reactions and quenching of the free radical inter-
mediate in solution. It is still not clear how the thioamide is 
oxidized by EthA. Tokuyama et al. demonstrated that a thio-
amide could be used as a precursor of a synthon equivalent to 
an imidoyl radical in converting thioamides to corresponding 
indole derivatives. Bu3SnH/Et3B has been used as a free radi-
cal initiator in pure organic solvent (25). Similarly, we postu-
late that ETH is converted to an imidoyl radical, and this 
imidoyl radical subsequently attacks NAD+ to form an ad-
duct, which is then converted to ethyl-isonicotinic-acyl-NAD 
adduct after hydrolysis to release the amine group. It is also 
possible that the imidoyl anion is the intermediate before 
forming the adduct with NAD (Fig. 5). However, based on 
the current evidence, we are not certain if this reaction is cat-
alyzed by EthA alone or requires the involvement of addi-
tional enzymes.
The experiments presented in this paper describe the 
molecular mechanism of the drug action of ETH and PTH 
against M. tuberculosis and M. leprae. The identifi  cation of the 
Figure 4.  Selected interactions between ETH-NAD and the active 
site of InhA. A conserved water molecule, TIP20, forms a hydrogen bond 
interaction with the nitrogen atom of the 2-ethyl-isonicotinic acyl moiety 
of the inhibitor at a distance of 2.9 Å. The other water molecule, TIP2, is in 
the center of a hydrogen bonding network, which interacts with the oxygen 
atom of the phosphate group of the adduct and the hydroxyl group of 
Ser94 at distances of 2.7 and 2.9 Å, respectively.
Figure 5.  Possible reaction mechanisms for the activation of ETH 
and the formation of ETH-NAD. Two plausible mechanisms for the 
activation of ETH are shown. Either route will lead to the observed ETH-
NAD adduct, retaining a tetrahedral carbon at position 4 of the nicotin-
amide ring.JEM VOL. 204, January 22, 2007  77
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ETH-NAD and PTH-NAD adducts, like the INH-NAD, 
represent a novel paradigm in the history of drug action. 
Eff  orts to detect the INH-NAD and ETH-NAD adduct 
in M. tuberculosis or other mycobacteria have been unsuc-
cessful. However, four diff  erent mechanisms of coresistance 
to INH and ETH have been discovered: (a) overexpres-
sion of the InhA target (6, 12); (b) target modifi  cation to 
prevent adduct binding (8); (c) activator modifi  cation to 
prevent prodrug activation and adduct formation (20); and 
(d) mutations in ndh, the gene encoding the essential NADH 
dehydrogenase II that regulates intracellular NADH/NAD 
ratios (26). All of these observations are consistent with 
our working model that INH, ETH, and PTH are all pro-
drugs that form NAD adducts to inhibit InhA. The dis-
covery of ETH-NAD and PTH-NAD adducts, which are 
generated through completely diff  erent routes from INH-
NAD, further validates this model. This information is 
important for the optimization of drug activity and the un-
derstanding of drug resistance. Because the molecular target 
of ETH, PTH, and INH is the same, it validates InhA as 
an outstanding antituberculosis and antileprosy drug target. 
However, because most of the clinical strains resistant to 
ETH and PTH contain mutations in the ethA gene, it is 
advantageous to fi  nd agents that inhibit InhA, without the 
need for EthA activation, as eff  ective chemotherapy against 
resistant bacteria.
MATERIALS AND METHODS
Cloning, expression, and purifi  cation. The M. tuberculosis inhA has been 
previously cloned (14). M. tuberculosis ethA was cloned from genomic DNA 
(National Institutes of Health contract N01-AI-75320; Colorado State 
  University). The amplifi  ed product was inserted into pET28b using the NdeI 
and NotI restriction sites. M. leprae ethA and inhA were cloned from geno-
mic DNA. The amplifi  ed product of M. leprae ethA was inserted into pET15b 
using the NdeI and BamHI restriction sites. M. leprae inhA was 
inserted into pET30b using the NdeI and HindIII restriction sites.
The plasmids of M. tuberculosis inhA and ethA were singly and doubly 
transformed into E. coli BL21 (DE3; EMD Biosciences, Inc.). The strain 
containing plasmids of inhA and ethA was cultured in LB-Miller media 
containing 50 μg/ml kanamycin and 50 μg/ml carbanicillin at 37°C 
until OD600 reached 0.8. Expression of both genes was induced for 20 h 
at 16°C by addition of 1 mM isopropyl β-D-thiogalactopyranoside. At 
the same time as induction, 100 μg/ml ETH or PTH was also added to 
the culture. The same protocol was used for the strain containing only the 
inhA plasmid.
Recombinant InhA was purifi  ed according to the previous method (14).
The coexpression and purifi  cation of M. leprae ethA and inhA were con-
ducted using protocols similar to those used for the M. tuberculosis enzymes.
Isolation and characterization of ETH-NAD and PTH-NAD. InhA 
purifi  ed from the experimental strain containing both inhA and ethA genes 
was concentrated and heated for 40 s at 100°C. After the heat treatment, 
ETH-NAD or PTH-NAD was separated from denatured enzymes by fi  ltra-
tion, using a centricon device (cutoff   size = 30 kD). The concentration of 
ETH-NAD and PTH-NAD was determined by its absorbance at 260 and 
326 nM (16). The molecular weight of both adducts was determined by 
  matrix-assisted laser desorption/ionization (MALDI) performed on an ABI 
Voyager-DE STR (AME Bioscience): ETH-NAD, calculated weight = 
797.2 and found weight = 797.3 (negative mode), and calculated weight = 
799.2 and found weight = 799.2 (positive mode); PTH-NAD, calculated 
weight = 811.2 and found weight = 811.3 (negative mode).
InhA enzymatic activity assay. All assays were performed on a spectro-
photometer (Cary 100 Bio Spectrophotometer; Varian, Inc.) at 25°C by 
monitoring oxidation of NADH at 340 nm. Reactions were initiated by 
adding 50 μM of substrate dodecenoyl-CoA to assay mixtures containing 
1 nM InhA, 100 μM NADH, and 3–2,000 nM of adduct inhibitors.
The IC50 was determined from the dose-response plot of enzyme frac-
tional activity as a function of inhibitor concentration. Ki was obtained by 
dividing the IC50 value by 1 + [S1]/Km1 + [S2]/Km2, where [S1] and [S2] are 
the concentrations of dodecenoyl-CoA and NADH, and Km1 and Km2 are 
their Michaelis constants.
Crystallization of InhA in complex with ETH-NAD adduct. Crystal-
lization was accomplished by the hanging drop vapor diff  usion method (27). 
M. tuberculosis InhA in complex with inhibitors was cocrystallized in hanging 
droplets containing 2 μl of protein solution at 10 mg/ml and 2 μl of buff  er 
(12% MPD, 4% DMSO, 0.1 M Hepes, 0.025 M sodium citrate) at 16°C in 
Linbro plates against 1 ml of the same buff  er. Diamond-shaped protein crys-
tals formed  4 d later.
M. leprae InhA in complex with inhibitor was cocrystallized in a similar 
manner, and the crystal had a cubic shape.
Data collection and processing. Data were collected at 121 K using 
cryoprotection solution containing reservoir solution with an additional 30% 
MPD. Crystals of M. tuberculosis InhA:ETH-NAD and M. leprae InhA:PTH-
NAD diff  racted x rays to 2.2 and 1.8 Å using the beamline 23-ID at the 
Advanced Photon Source (Argonne National Laboratory, Argonne, IL). 
Diff  raction data were collected from a single crystal with 1° oscillation widths 
for a range of 120°. Crystals of M. tuberculosis InhA:PTH-NAD were dif-
fracted to 2.5 Å using a Raxis image plate detector coupled to a Rigaku 
x-ray generator using a copper rotating anode (CuKα, λ = 1.54 Å). The 
data were integrated and reduced using HKL-2000 (HKL Research, Inc.; 
Table S1) (28).
Structure determination and model refi  nement. Crystals produced 
from InhA in complex with ETH-NAD were isomorphous to those of the 
native enzyme. Initial phases were obtained by molecular replacement using 
the apo-InhA structure (1ENY) and refi  ned with CNS software (Table S1) 
(29). Fo – Fc and 2Fo – Fc electron density maps were calculated, and an ad-
ditional density resembling the inhibitor was found. The ligand was fi  t into 
the additional density, and the whole model was rebuilt using XtalView (30). 
During the fi  nal cycles of the refi  nement, water molecules were added into 
peaks above 3 σ of the Fo − F c electron density maps that were within 
hydrogen-bonding distances from the appropriate protein atoms. The fi  nal 
refi  nement statistics are listed in Table S1.
Online supplemental material. Table S1 provides data collection, pro-
cessing, and refi  nement statistics. Fig. S1 depicts MALDI mass spectra show-
ing that two inhibitors bound to InhA are compounds with the apparent 
weights of 798 and 812, respectively. Fig. S2 shows the crystal structure of 
the adducts superimposed onto the simulated annealing omit electron den-
sity maps contoured at 1 and 1.5 σ. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20062100/DC1.
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